Cadila Pharmaceuticals inaugurated its cutting-edge Active Pharmaceutical Ingredients (API) Plant in Dahej, Bharuch district, with a Rs. 200 crore investment. The facility boasts state-of-the-art Distributed Control System (DCS) automation technology, underscoring Cadila Pharmaceuticals’ commitment to innovation and excellence in drug manufacturing.
The inauguration of Cadilla Pharmaceuticals new plant was graced by HG Koshia, Commissioner of Food and Drugs Control Administration (FDCA), Gujarat, alongside Dr. M P Nakarani, Assistant Commissioner of FDCA, Baruch Circle, and other dignitaries, industry leaders, and pharma representatives, marked a significant moment in the company’s journey.
Dr. Koshia praised the facility, attributing its inspiration to the late Shri IA Modi, the driving force behind the Indian pharma industry. Cadila Pharmaceuticals’ Chief Mentoring Officer, Biswajit Mitra, highlighted the facility’s commitment to providing high-quality, cost-effective APIs globally. The DCS technology ensures purity, consistency, and reduced environmental impact, contributing to the facility’s efficiency and its role in meeting rising product demands.
Cadila Pharmaceuticals Limited, headquartered in Ahmedabad, Gujarat, is a leading and fully integrated private pharmaceutical company in India. Known for its expertise in developing and manufacturing a wide range of pharmaceutical products, the company has expanded its global footprint, distributing and selling in over 100 countries. Cadila Pharmaceuticals is deeply committed to research, with a focus on diverse fields like biotechnology, active pharmaceutical ingredients (APIs), formulations, plant tissue culture, and phytochemistry.
The company excels in various therapeutic domains, including gastrointestinal, cardiology, pulmonary, oncology, gynecology, cardiovascular, diabetology, and osteology. Emphasizing the creation of affordable healthcare solutions, Cadila Pharmaceuticals targets areas with significant unmet medical needs. This commitment has led to remarkable innovations and several world-first breakthroughs, solidifying the company’s reputation as a pioneer in the pharmaceutical industry.
Biswajit Mitra, Chief Mentoring Officer at Cadila Pharmaceuticals, emphasized the significance of the new API manufacturing facility in Dahej. Highlighting the company’s commitment to delivering high-quality and cost-effective APIs worldwide, he focused on the utilization of DCS technology in the facility. It ensures the production of APIs with elevated purity and consistency, while minimizing environmental impact. Engineered for efficiency, the facility is poised to address the increasing demand for Cadila Pharmaceuticals’ products, contributing significantly to the company’s future success.
This API plant is part of Cadila Pharmaceuticals’ Rs. 1,000 crore investment commitment to Gujarat, as outlined in a previous MoU with the state government. The facility not only meets the company’s standards for product quality but also positions it to venture into new markets. With a focus on sustainability, the facility aligns with Cadila Pharmaceuticals’ environmental initiatives, reflecting its dedication to advancing healthcare solutions through cutting-edge technology and eco-friendly practices.
